The skeleton: stone bones and stoned heads?

  • Itai A. Bab
Part of the Milestones in Drug Therapy MDT book series (MDT)


Osteoclast Differentiation Glyceryl Ether Regulate Bone Formation Osteogenic Growth Peptide Mature Osteoblastic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Karsenty G (2001) Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res 56: 401–415CrossRefPubMedGoogle Scholar
  2. 2.
    Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27: 1229–1241CrossRefPubMedGoogle Scholar
  3. 3.
    Parfitt AM (1982) The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis Metab Bone Dis Relat Res 4: 1–6CrossRefPubMedGoogle Scholar
  4. 4.
    Bab I, Ashton B.A, Gazit D, Marx G, Williamson MC, Owen ME (1986) Kinetics and differentiation of marrow stromal cells in diffusion chambers in vivo. J Cell Sci 84: 139–151PubMedGoogle Scholar
  5. 5.
    Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115–137CrossRefPubMedGoogle Scholar
  6. 6.
    Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F (1994) Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13: 1189–1196PubMedGoogle Scholar
  7. 7.
    Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N (2001) The molecular basis of osteoclast differentiation and activation. Novartis Found Symp 232: 235–247PubMedGoogle Scholar
  8. 8.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319CrossRefPubMedGoogle Scholar
  9. 9.
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176CrossRefPubMedGoogle Scholar
  10. 10.
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL et al. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Gene Dev 12: 1260–1268PubMedGoogle Scholar
  11. 11.
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315–323CrossRefPubMedGoogle Scholar
  12. 12.
    Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T et al. (2000) Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103: 1085–1097CrossRefPubMedGoogle Scholar
  13. 13.
    Most W, van der Wee-Pals L, Ederveen A, Papapoulos S, Lowik C (1997) Ovariectomy and orchidectomy induce a transient increase in the osteoclastogenic potential of bone marrow cells in the mouse. Bone 20: 27–30CrossRefPubMedGoogle Scholar
  14. 14.
    Alexander JM, Bab I, Fish S, Mueller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M et al. (2001) Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. J Bone Min Res 16: 1665–1673Google Scholar
  15. 15.
    Potts JT, Juppner H (1998) Parathyroid hormone and parathyroid hormone-related peptide. In: Calcium homeostasis, bone metabolism, and bone development: the proteins, their genes, and receptors. Academic Press, San DiegoGoogle Scholar
  16. 16.
    Gunther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, Moseley JM, Martin TJ, Anderson DJ, Karsenty G (2000) Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 406: 199–203CrossRefPubMedGoogle Scholar
  17. 17.
    Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ (1986) Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest 78: 355–360PubMedGoogle Scholar
  18. 18.
    Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D (2002) Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110: 771–781CrossRefPubMedGoogle Scholar
  19. 19.
    Bab I, Chorev M (2002) Osteogenic growth peptide: from concept to drug design. Biopolymers 66: 33–48CrossRefPubMedGoogle Scholar
  20. 20.
    Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197–207CrossRefPubMedGoogle Scholar
  21. 21.
    Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H (2002) Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109: 915–921CrossRefPubMedGoogle Scholar
  22. 22.
    Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305–317CrossRefPubMedGoogle Scholar
  23. 23.
    Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822–825CrossRefPubMedGoogle Scholar
  24. 24.
    Orzel JA, Rudd TG (1985) Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med 26: 125–132PubMedGoogle Scholar
  25. 25.
    Wildburger R, Zarkovic N, Tonkovic G, Skoric T, Frech S, Hartleb M, Loncaric I, Zarkovic K (1998) Post-traumatic hormonal disturbances: prolactin as a link between head injury and enhanced osteogenesis. J Endocrinol Invest 21: 78–86PubMedGoogle Scholar
  26. 26.
    Panikashvili D, Simeonidou C, Ben-Shabat S, Hanug L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527–531CrossRefPubMedGoogle Scholar
  27. 27.
    Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S (1983) In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96:191–198CrossRefPubMedGoogle Scholar
  28. 28.
    Jorgensen NR, Henriksen Z, Sorensen OH, Civitelli R (2004) Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts. Steroids 69: 219–226CrossRefPubMedGoogle Scholar
  29. 29.
    Maccarrone M, Finazzi-Agro A (2002) Endocannabinoids and their actions. Vitam Hormone 65: 225–255Google Scholar
  30. 30.
    Bellows CG, Aubin JE, Heersche JN, Antosz ME (1986) Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 38: 143–154PubMedGoogle Scholar
  31. 31.
    Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ, Ng KW (1994) In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Min Res 9:1489–1499Google Scholar
  32. 32.
    Zhang RW, Supowit SC, Xu X, Li H, Christensen MD, Lozano R, Simmons DJ (1995) Expression of selected osteogenic markers in the fibroblast-like cells of rat marrow stroma. Calcif Tissue Int 56: 283–291CrossRefPubMedGoogle Scholar
  33. 33.
    Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS (2004) Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14: 1–41PubMedGoogle Scholar
  34. 34.
    Zou W, Schwartz H, Endres S, Hartmann G, Bar-Shavit Z (2002) CpG oligonucleotides: novel regulators of osteoclast differentiation. FASEB J 16: 274–282CrossRefPubMedGoogle Scholar
  35. 35.
    Hanug L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228–14233CrossRefPubMedGoogle Scholar
  36. 36.
    Hanug L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98: 3662–3665CrossRefPubMedGoogle Scholar
  37. 37.
    Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J (1995) Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 34: 175–180CrossRefPubMedGoogle Scholar
  38. 38.
    Karsak M, Ofek O, Fogel M, Wright K, Tam J, Gabet Y, Birenboim R, Attar-Namdar M, Müller R et al. (2004) The cannabinoid CB2 receptor: a potential target for the diagnosis and treatment of osteoporosis. J Bone Min Res 9: S383Google Scholar
  39. 39.
    Iuliano-Burns S, Mirwald RL, Bailey DA (2001) Timing and magnitude of peak height velocity and peak tissue velocities for early, average, and late maturing boys and girls. Am JHum Biol 13:1–8CrossRefGoogle Scholar
  40. 40.
    Baxter-Jones AD, Mirwald RL, McKay HA, Bailey DA (2003) A longitudinal analysis of sex differences in bone mineral accrual in healthy 8-19-year-old boys and girls. Ann Hum Biol 30:160–175CrossRefPubMedGoogle Scholar
  41. 41.
    Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ (1984) Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1(8386): 1091–1093CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2005

Authors and Affiliations

  • Itai A. Bab
    • 1
  1. 1.Bone LaboratoryThe Hebrew University of JerusalemJerusalemIsrael

Personalised recommendations